ReviewFrontiers in neurology2026
Single-cell and single-nucleus transcriptomics in ischemic stroke: cellular mechanisms and therapeutic implications.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke remains a major cause of death and long-term disability and is defined by complex, dynamic pathophysiological processes involving diverse cell types and interconnected molecular networks. In recent years, single-cell and single-nucleus RNA sequencing (sc/snRNA-seq) have provided unmatched resolution for dissecting these processes. A growing body of studies has applied these approaches to ischemic stroke, generating extensive insight into cellular heterogeneity, molecular regulation, and disease-associated cell states. This review systematically integrates current evidence from sc/snRNA-seq studies, with a primary focus on brain-intrinsic mechanisms after ischemic stroke. Existing findings are organized across major pathophysiological domains, including immune and inflammatory responses, blood-brain barrier (BBB) disruption and angiogenesis, regulated cell death, metabolic dysregulation, aging and cellular senescence, and neuroregeneration and remyelination. Beyond these canonical mechanisms, we summarize emerging applications of sc/snRNA-seq in extra-CNS systems, distinct biological contexts, and stroke-related complications. We also highlight how sc/snRNA-seq has been used to investigate therapeutic mechanisms, including physical and neuromodulatory interventions, pharmacological agents, cell-based therapies, and bioengineered delivery systems. Together, this review provides a structured synthesis of how sc/snRNA-seq has advanced the understanding of ischemic stroke biology by identifying disease-relevant cell states, refining mechanistic targets, and informing future translational development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.